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SYNOPSIS
Objective. The purpose of this study was to analyze enrollment of racial/ethnic
minorities in Phase I and Phase II HIV vaccine trials in the U.S. conducted by
National Institute of Allergy and Infectious Diseases (NIAID)-funded networks from
1988 to 2002.
Methods. A centralized database was searched for all NIAID-funded networks of
HIV vaccine trial enrollment data in the U.S. from 1988 through 2002. The authors
reviewed data from Phase I or Phase II preventive HIV vaccine trials that included
HIV-1 uninfected participants at low to moderate or high risk for HIV infection
based on self-reported risk behaviors. Of 66 identified trials, 55 (52 Phase I, 3
Phase II) met selection criteria and were used for analyses. Investigators extracted
data on participant demographics using statistical software.
Results. A total of 3,731 volunteers enrolled in U.S. NIAID-funded network HIV
vaccine trials from 1988 to 2002. Racial/ethnic minority participants represented 17%
of the overall enrollment. By pooling data across all NIAID-funded networks from
1988 to 2002, the proportion of racial/ethnic minority participants was significantly
greater (Fisher’s exact test p-value 0.001) in Phase II trials (278/1,061 or 26%) than
in Phase I trials (347/2,670 or 13%). By generalized estimating equations, the
proportion of minorities in Phase I trials increased over time (p=0.017), indicating a
significant increase in racial/ethnic minority participants from 1988 to 2002.
Conclusions. There has been a gradual increase in racial/ethnic minority participa-
tion in NIAID-funded network HIV vaccine trials in the U.S. since 1988. In the light
of recent efficacy trial results, it is essential to continue to increase the enrollment
of diverse populations in HIV vaccine research.
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HIV vaccine development is a critical path in developing a
long-term strategy to control the worldwide HIV epidemic.1
The evaluation of candidate preventive HIV vaccines is a
priority for the National Institute of Allergy and Infectious
Diseases (NIAID) of the National Institutes of Health (NIH),
which provides funding and support for preventive HIV
vaccine trials both domestically and internationally.2,3 Test-
ing safety and immunogenicity of candidate preventive HIV
vaccines has been in progress since 1987.
In 2003, the Centers for Disease Control and Prevention
(CDC) surveillance report indicated that approximately 50%
of newly detected HIV infections occurred among African
Americans and 19% among Hispanic/Latinos,4 highlighting
a disparity in the infection rates. Because racial/ethnic mi-
norities are disproportionately represented in the HIV epi-
demic in the U.S.,4 it is important that HIV vaccine clinical
trials be designed and enrolled with adequate representa-
tion of these groups, especially African Americans, so that
the findings of trials are credible both to scientists and to
affected communities. Furthermore, NIH has a mandate,
based on the ethical principle of justice,5 to include more
minorities and women in clinical research.6
A recent privately-sponsored Phase III HIV vaccine trial
including relatively small numbers of participants of color
concluded that crude vaccine efficacy rates were higher
among black and Asian participants.7 The significance of
this result continues to be debated, as the number of cases
and participants were few, and definitive conclusions as to
whether racial factors influence transmission are not avail-
able. All of these factors highlight the importance of enroll-
ing sufficiently large numbers of racial/ethnic minorities in
HIV clinical trials.
 In this analysis, we examine the enrollment of racial/
ethnic minorities in Phase I and Phase II HIV vaccine trials
conducted by NIAID-funded networks in the United States
from 1988 to 2002, and analyze enrollment trends. We also
discuss strategies for increasing enrollment of racial/ethnic
minorities in future HIV vaccine trials.
METHODS
We reviewed all enrollment data in the U.S. on preventive
HIV vaccine trials conducted by NIAID-funded networks
between 1988 and 2002. We also examined Phase I and II
trials evaluating candidate preventive HIV vaccines for safety
and immunogenicity in HIV-1–negative participants older
than age 18. From 1988 to 2000, such trials were conducted
by NIAID’s AIDS Vaccine Evaluation Group (AVEG), and
one trial was conducted as a collaboration between AVEG
and the HIV Network for Prevention Trials (HIVNET). In
2000, when the HIV Vaccine Trials Network (HVTN) re-
placed AVEG/HIVNET, AVEG completed enrollment for
existing trials while HVTN began enrollment for new trials.
AVEG/HIVNET included 15 trial sites: San Francisco,
Birmingham, Baltimore (2), Rochester (NY), St. Louis, Nash-
ville, Seattle (2), Philadelphia, Chicago, Boston, New York
(2), and Denver. As of 2002, HVTN, serving as an interna-
tional network to test candidate HIV vaccines, included 13
U.S. trial sites: San Francisco, Birmingham, Baltimore (2),
Rochester (NY), St. Louis, Nashville, Seattle, Boston (3),
New York (2). Six sites were common to both networks.
HVTN also includes 17 non-U.S. trial sites and one trial site
in Puerto Rico. Because the focus of this study was minority
enrollment in the U.S., for this analysis we included partici-
pants enrolled at HVTN sites in the U.S. only.
Study participants
Study participants were recruited by various methods (e.g.,
person-to-person, media, contact lists) and were eligible for
enrollment according to individual study protocol require-
ments. Generally, participants were eligible if they were in
good general health and confirmed to be HIV-1 uninfected.
Health history and physical and laboratory exams were used
to identify and exclude subjects with pre-existing medical
conditions that could affect the safety of the participant or
compromise safety or immunogenicity evaluations during
the trial. In addition, participants provided informed con-
sent for participation in the vaccine trial. Demographic data,
including age, gender, race/ethnicity, and sexual orienta-
tion, were collected from each volunteer by interview.
Phase I and Phase II studies enrolled individuals at low to
moderate or high risk for HIV infection based on self-re-
ported risk (sex and injecting drug use) behaviors. Most of
the Phase I studies enrolled volunteers who met criteria
likely to predict a low risk for acquiring HIV-1. Phase II trials
included volunteers at higher risk for acquiring HIV-1 to
further assess vaccine safety and immunogenicity in a popu-
lation similar to that needed for efficacy trials.
Data management and statistical methods
All data were collected using a distributed data entry system,
with information sent weekly to a central database. Statisti-
cal analyses were conducted using SAS version 8.2.8 We tabu-
lated frequencies for demographic characteristics for all vol-
unteers enrolled in Phase I and Phase II trials. Racial/ethnic
categories were defined as “white, non-Hispanic/Latino” and
“racial/ethnic minority,” because of the low numbers of all
racial/ethnic categories other than white. Racial/ethnic
minority included African American, Hispanic/Latino (of
all races, including white), Asian/Pacific Islander, Native
American, multiracial, and other. Race/ethnicity was self-
identified. Participants could select only one racial category.
In the AVEG data system prior to March 1993, Hispanic
was one of the choices in the race category. After 1993,
participants were asked two questions about race and
ethnicity: first, a question about Hispanic ethnicity, and then
a separate question about race. All participants who had
selected Hispanic in the ethnicity category prior to 1993
were mapped to Hispanic in the new ethnicity category, and
were re-contacted to obtain their self-reported racial iden-
tity. The race designation was then updated in the dataset.
The current HVTN data system asks race and ethnicity in
the same way as the post-1993 AVEG system, in that race and
ethnicity are asked separately. In the HVTN system, the
ethnicity category includes “Hispanic or Latino.”
To assess trends in enrollment of white, non-Hispanic/
Latino participants, we considered AVEG, HIVNET, and
HVTN enrollment data. These data included enrollment of
3,731 volunteers at all sites over a 15-year period (1988 to
2002). HVTN Phase I recruitment is ongoing; participants
enrolled before May 15, 2002, are included in this analysis.
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We excluded Phase II data from the trend analysis be-
cause Phase II trials were few in number and conducted with
large time lapses between them, making the data temporally
disjointed. In addition, Phase II trials enroll participants
under different behavioral risk criteria, so trends of racial/
ethnic minority enrollment are difficult to compare directly.
We represented the proportion of racial/ethnic minority
participants graphically by year of enrollment. Univariate
plots, statistics, and summary measures were used as an ini-
tial step in the data analysis. To examine time trends more
formally, we modeled the log odds of enrolling racial/eth-
nic minority participants as a function of calendar time.
Generalized estimating equations9 (GEE) were employed to
account for possible correlation induced by repeated mea-
surements within particular sites over time. Assessing the
significance of time effects was based on the generalized
score statistic.10 A modified version of the Akaike Informa-
tion Criterion was employed for model selection.11 We treated
time as a continuous covariate with likelihood ratio tests
employed to test for trends. All statistical tests were done at
the 0.05 significance level.
RESULTS
Volunteer enrollment
A total of 3,731 volunteers enrolled in U.S. preventive HIV
vaccine trials from 1988 to 2002 (see Table): 2,670 enrolled
in 52 Phase I trials, and 1,061 enrolled in three Phase II
trials. A total of 11 trials were excluded because they en-
rolled HIV-positive participants. Overall, 3,207 (86%) volun-
teers enrolled in AVEG trials and the AVEG/HIVNET col-
laborative trial, and 524 (14%) volunteers enrolled in HVTN
trials. Of these, 1,442 (39%) were women. Racial/ethnic
minority participants represented 17% of the overall enroll-
ment, comprised of African American (10%), Hispanic/
Latino (4%), Asian/Pacific Islander (1%), Native American
(0.6%), multiracial (1%), and other (1%).
Enrollment trends of racial/ethnic minorities
Pooling data across AVEG, HIVNET, and HVTN from 1988
to 2002, the proportion of racial/ethnic minority partici-
pants was significantly greater (Fisher’s exact test p-value
0.001) in Phase II trials (278/1,061 or 26%) than in Phase
Table. Enrollment demographics by Phase I and Phase II trials and by AVEG, HIVNET. and HVTN, 1988 to 2002
N (percent)
Phase Network
Characteristic Total N (percent) I II AVEG, HIVNET HVTN
Gender
Female 1,442 (38.6) 1,143 (42.8) 299 (28.2) 1,272 (39.7) 170 (32.4)
Male 2,289 (61.4) 1,527 (57.2) 762 (71.8) 1,935 (60.3) 354 (67.6)
Age (years)
20 116 (3.1) 100 (3.7) 16 (1.5) 106 (3.3) 10 (1.9)
20–29 1,198 (32.1) 929 (34.8) 269 (25.4) 1,022 (31.9) 176 (33.6)
30–39 1,263 (33.9) 855 (32.0) 408 (38.5) 1,093 (34.1) 170 (32.4)
40–49 893 (23.9) 603 (22.6) 290 (27.3) 757 (23.6) 136 (26.0)
50+ 261 (7.0) 183 (6.9) 78 (7.4) 229 (7.1) 32 (6.1)
Race/ethnicity
White 3,106 (83.2) 2,323 (87.0) 783 (73.8) 2,697 (84.1) 409 (78.1)
Black 377 (10.1) 192 (7.2) 185 (17.4) 309 (9.6) 68 (13.0)
Hispanic/Latino 157 (4.2) 90 (3.4) 67 (6.3) 134 (4.2) 23 (4.4)
Asian/Pacific Islander 47 (1.3) 37 (1.4) 10 (0.9) 37 (1.2) 10 (1.9)
Native American 23 (0.6) 17 (0.6) 6 (0.6) 17 (0.5) 6 (1.1)
Multiracial 4 (0.1) 4 (0.1) 0 (0.0) 0 (0.0) 4 (0.8)
Other 17 (0.5) 7 (0.3) 10 (0.9) 13 (0.4) 4 (0.8)
Sexual orientation
Homosexual 1,466 (39.3) 909 (34.0) 557 (52.5) 1,239 (38.6) 227 (43.3)
Heterosexual 2,022 (54.2) 1,602 (60.0) 420 (39.6) 1,769 (55.2) 253 (48.3)
Bisexual 197 (5.3) 143 (5.4) 54 (5.1) 153 (4.8) 44 (8.4)
Missing 46 (1.2) 16 (0.6) 30 (2.8) 46 (1.4) 0 (0.0)
Total 3,731 2,670 1,061 3,207 524
AVEG  AIDS Vaccine Evaluation Group
HIVNET  HIV Network for Prevention Trials
HVTN  HIV Vaccine Trials Network
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I trials (347/2,670 or 13%). Given the paucity of Phase II
trials from 1988 to 2000, we modeled trends in minority
enrollment for Phase I trials and provided descriptive data
only for Phase II trials.
For Phase I trials, the proportion of minority participants
by year of enrollment is represented in the Figure. The
percentage of racial/ethnic minority participants ranged
from 0% (0/76 in 1988 and 0/67 in 1990) to 30% (52/172
in 2002). GEE models with constant, linear, quadratic, and
cubic time components each indicated a statistically signifi-
cant increase in the proportion of racial/ethnic minority
enrollment in Phase I trials over the time period considered.
The modified Akaike Information Criterion indicated that
the cubic model with an autoregressive working correlation
structure provided the best fit of the models considered. For
this model, the generalized score test for a time trend gave
a p -value of 0.017, indicating a significant increase in racial/
ethnic minority participants from 1988 to 2002.
Three protocols were included in the analysis of Phase II
trials: AVEG 201, AVEG 202/HIVNET 014, and HVTN 203.
Of the 296 participants enrolled in AVEG 201 (1992 and
1993), 78 (26.4%) were categorized as racial/ethnic minor-
ity. The greatest proportion of minority enrollment in a
Phase II trial occurred from 1997 to 1998, where 142 of 435
(32.6%) of participants in AVEG 202/HIVNET 014 were
categorized as racial/ethnic minority. For HVTN 203, 17.6%
(58/330) of participants enrolled during 2000 and 2001
were racial/ethnic minority.
DISCUSSION
From 1988 to 2002, the proportion of participants of color
in NIAID-network funded Phase I HIV preventive vaccine
trials in the U.S. increased.
Since 1994, NIH medical research policies have man-
dated the inclusion of women and racial/ethnic minorities
in clinical trials.12 While minority enrollment has increased
in the trials examined here, barriers still exist that affect
adequate recruitment and retention of racial/ethnic mi-
norities into clinical trials. These may include, among oth-
ers, level of access to health coverage and financial resources;
minority-held attitudes, beliefs, and perceptions about clini-
Figure. Minority (non-white, non-Hispanic) enrollment among participants in Phase I
HIV vaccine trials represented by year
NOTE: By generalized estimating equations, the proportion of minorities in Phase I trials increased over time (p=0.017).
AVEG = AIDS Vaccine Evaluation Group
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cal research; or level of knowledge regarding clinical re-
search.13–15 Further assessment on the effectiveness of strate-
gies to increase minority participation in clinical research in
the U.S. is needed.16
There are important reasons why further efforts to sus-
tain and increase minority enrollment in HIV vaccine trials
are needed. First, the NIH has a mandate to increase enroll-
ment of women and minorities in all federal government-
supported clinical research. Furthermore, it is important to
ensure adequate representation of racial/ethnic minorities
in vaccine trials because a licensed vaccine will eventually be
offered to some members of these same communities by the
public health system. It is important to increase acceptability
of efficacy trials as well as an eventually licensed vaccine.
Issues of trust in public health institutions and research
programs are complex in communities of color in the United
States. For example, mistrust among African Americans may
be influenced by the federal government’s Tuskegee syphilis
experiment of the 1930s to 1970s; the history of this pro-
gram still presents challenges to the provision of prevention
services to some communities.17,18 In addition to mistrust of
research, social stigma related to HIV is another barrier to
participation in trials that can be especially acute in commu-
nities of color.19–22 The lesson for HIV vaccine development
is that early and meaningful involvement of communities of
color in HIV vaccine trials is important to building trust with
communities, and to ensuring that there is a track record of
safety and efficacy of candidate vaccines trials that have
included racial/ethnic minorities.
Second, there are important ethical reasons to ensure
access of HIV vaccine trials to racial/ethnic minorities, espe-
cially since those communities are disproportionately affected
by the HIV/AIDS epidemic.4 Access to vaccine trials may
promote the ethical principle of justice and beneficence
across communities. In addition, NIH-sponsored vaccine
research bears the responsibility to educate, inform, and
involve communities in all aspects of vaccine research, which
can help to reduce the stigma arising from prejudice about
HIV.
From an operational point of view, there may be situa-
tions where sufficient statistical power to conduct analyses of
vaccine efficacy by racial/ethnic subgroup will be desirable.
Results from the first HIV vaccine efficacy trial (conducted
by VaxGen, Inc.)7 suggested that the efficacy rate among
black and Asian participants was higher than the efficacy
rate among white participants. These findings were very
difficult to interpret, however, because (1) subgroup analy-
sis was not initially planned, (2) a low number of partici-
pants of color were enrolled, and (3) the number of HIV
infections among participants of color was small.
Underlying the discussion of results from the VaxGen
efficacy trial was the possibility that a vaccine might be vari-
ably efficacious in different racial/ethnic groups for a ge-
netic reason. Although it seems most likely that there would
not be a biologic basis for variations in vaccine efficacy
among different racial/ethnic groups, it is plausible that
differences in response to a vaccine could occur based on
variations in Human Leukocyte Antigen (HLA) or antibody
response profiles associated with race/ethnicity.23–25 There
are, however, behaviorally mediated reasons that preventive
HIV vaccine efficacy may vary among racial/ethnic groups.
Recent data illustrating a stark difference in HIV incidence
rates among young gay men in urban areas by race/ethnicity27
suggest that there may be important differences by race/
ethnicity in patterns of exposure or density of exposure to
HIV among men who have sex with men, who will be an
important pool of volunteers in future U.S. efficacy trials.
Although HVTN trials typically collect risk behavior infor-
mation on all trial participants, it is important to ensure that
these highest-risk people are well represented in the trials.
Overall vaccine effectiveness may also depend upon the de-
gree to which vaccine recipients engage in high-risk behav-
iors because they believe that vaccination protects them,
although recent Phase III trial results do not show this to be
the case.7,26 Monitoring changes in risk behaviors during the
conduct of an efficacy trial will be important, and we must
measure whether changes in risk behavior after vaccination
vary among racial/ethnic groups.
The data and our analyses have important limitations.
We did not attempt to associate increased proportions of
participants of color in HIV vaccine trials with underlying
changes in the demographic characteristics of the popula-
tions in the areas where the trials were conducted. There-
fore, it is possible that some portion of the increased repre-
sentation of participants of color simply reflects an increasing
awareness of HIV and research among people of color in
communities where trials were conducted. The increase in
minority participation in HVTN trials as of 2000 may also be
due to the fact that such participation was aggressively sought.
However, the rate of increase in enrollment of people of
color over time suggests other factors may have played a
role.
While this paper did not focus on the effectiveness of
past enrollment approaches, HVTN is pursuing multiple
strategies to sustain and increase the enrollment of greater
racial/ethnic diversity in HIV vaccine trials in the future.
HVTN investigators at U.S. sites are developing plans to
increase recruitment of volunteers for HIV vaccine trials by
beginning or increasing advertising in media that reach
large numbers of potential participants of color. The HVTN
has made educational and consent materials available in
languages other than English, employed racially/ethnically
diverse staff, and involved community leaders from minority
communities in HIV Vaccine Community Advisory Boards.
Furthermore, in recognition of future needs, HVTN leader-
ship committed additional funding in 2003 to fighting the
legacy of the Tuskegee trial and to increasing minority en-
rollment in HVTN trials.
Globally, HVTN has developed HIV vaccine trial units in
Asia, Africa, South America, and the Caribbean, and is in
the process of expanding in those areas. This expansion will
result in larger numbers of participants of color, involve-
ment in the vaccine development process of communities
most affected by HIV, and greater experience with HIV vac-
cines in populations with varied HLA constitutions. Although
increased enrollment of racial/ethnic minorities at interna-
tional sites may help address concerns about biologic factors
related to vaccine efficacy, issues of trust between the Afri-
can American community and the public health system in
the United States call for a sustained effort to engage diverse
communities in vaccine clinical trials in the U.S.
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